SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022.
11th Annual SVB Leerink Global Healthcare Conference - Virtual
Event Dates: February 14...
>>> Read more: Immutep to Present at February Investor Conferences
11th Annual SVB Leerink Global Healthcare Conference - Virtual
Event Dates: February 14...
>>> Read more: Immutep to Present at February Investor Conferences
